000			02166 a2200613 4500
005			20250513031357.0
264		0	_c19950223
008			199502s 0 0 eng d
022			_a0340-7004
024	7		_a10.1007/BF01517234 _2doi
040			_aNLM _beng _cNLM
100	1		_aVlasveld, L T
245	0	0	_aTreatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. _h[electronic resource]
260			_bCancer immunology, immunotherapy : CII _cJan 1995
300			_a37-47 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xadverse effects
650	0	4	_aAntigen-Antibody Reactions
650	0	4	_aAntigens, CD _ximmunology
650	0	4	_aAntigens, CD19
650	0	4	_aAntigens, Differentiation, B-Lymphocyte _ximmunology
650	0	4	_aB-Lymphocytes _ximmunology
650	0	4	_aCombined Modality Therapy
650	0	4	_aComplement System Proteins _xmetabolism
650	0	4	_aCytotoxicity, Immunologic
650	0	4	_aDose-Response Relationship, Immunologic
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunoglobulins _xblood
650	0	4	_aImmunophenotyping
650	0	4	_aInfusions, Intravenous
650	0	4	_aInterleukin-2 _xadverse effects
650	0	4	_aLeukocyte Count
650	0	4	_aLymphocyte Activation
650	0	4	_aLymphoma, Non-Hodgkin _ximmunology
650	0	4	_aMale
650	0	4	_aMice
650	0	4	_aMiddle Aged
650	0	4	_aReceptors, Interleukin-2 _xmetabolism
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aT-Lymphocytes _ximmunology
700	1		_aHekman, A
700	1		_aVyth-Dreese, F A
700	1		_aMelief, C J
700	1		_aSein, J J
700	1		_aVoordouw, A C
700	1		_aDellemijn, T A
700	1		_aRankin, E M
773	0		_tCancer immunology, immunotherapy : CII _gvol. 40 _gno. 1 _gp. 37-47
856	4	0	_uhttps://doi.org/10.1007/BF01517234 _zAvailable from publisher's website
999			_c7529632 _d7529632